Verificando…
Traduzido automaticamente. Doses e advertências: confira o original em inglês. Ler em inglês
Início / Registado na Nigéria / Novalor Syrup

Novalor Syrup

NAFDAC Reg. No. 04-1636 · Drug

Registered with NAFDAC. Registration activeAs of 4 November 2026 · synced automatically from official sources.
Product
Novalor Syrup
Número NAFDAC
04-1636
Princípio ativo
Chloroquine (Chloroquine Phosphate)
Dosagem
50 mg/5 mL
Forma
Syrup
Tamanho da embalagem
1 x 60 mL (in amber colored PET bottle)
Manufacturer
Not listed
Applicant (holder)
SKG - Pharma Ltd
Approved
26 Aug 2021
Situação
Inactive View on NAFDAC ↗
Registro válido até
25 Aug 2026
Alertas da OMS
None found
Community reports
None
Times checked
0

About the medicine: Chloroquine: uses, dosage and brands worldwide

What we found

  • Novalor Syrup is on the NAFDAC register with an active registration (04-1636). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Novalor Syrup

O que diz a bula oficial. Se um médico receitou, siga a receita. Se a bula da sua caixa for diferente, vale a da sua caixa.

Para quem é

Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). …

Como tomar e com que frequência
  • The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base
  • Each 500 mg tablet of Chloroquine phosphate contains the equivalent of 300 mg chloroquine base
  • In infants and children the dosage is preferably calculated by body weight
  • Prophylaxis against chloroquine-sensitive Plasmodium species Adult Dose: The dosage for prophylaxis is 500 mg (= 300 mg base) administered once per week on exactly the same day of each week
  • Pediatric Dose : The dosage for prophylaxis is 5 mg calculated as base, per kg of body weight, administered once per week on exactly the same day of each week
  • The pediatric dose should never exceed the adult dose regardless of weight
  • If circumstances permit, suppressive therapy should begin two weeks prior to exposure
  • However, failing this
  • In adults, an initial double (loading) dose of 1 g (= 600 mg base), or in children 10 mg base/kg may be taken in two divided doses, six hours apart
  • The suppressive therapy should be continued for eight weeks after leaving the endemic area
  • Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species
  • Adults : An initial dose of 1 g salt (= 600 mg base) followed by an additional 500 mg (= 300 mg base) after six to eight hours and a single dose of 500 mg (= 300 mg base) on each of two consecutive days
  • This represents a total dose of 2.5 g chloroquine phosphate or 1.5 g base in three days
  • Infants and Children: In infants and children, the recommended dose is 10 mg base/kg followed by 5 mg based/kg at 6, 24 and 36 hours (total dose 25 mg based/kg). …
Talk to a doctor first if
  • Use of chloroquine phosphate tablets for indications other than acute malaria is contraindicated in the presence of retinal or visual field changes of any etiology
  • Use of chloroquine phosphate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds
Warnings

Chloroquine-Resistant Malaria Chloroquine phosphate tablets are not effective against chloroquine-or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY , Microbiology ). Chloroquine resistance is widespread in P. falciparum and is reported in P. vivax . Before using chloroquine for prophylaxis, it should be ascertained whether chloroquine is appropriate for use in the region to be visited by the traveler. Information regarding the geographic areas where resistance to chloroquine occurs, is available at the Centers for Disease Control and Prevention (www.cdc.gov\malaria). …

Possíveis efeitos colaterais

The following adverse reactions have been identified during post-approval use of chloroquine or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular disorders: Maculopathy and macular degeneration have been reported and may be irreversible. Irreversible retinopathy with retinal pigmentation changes (bull’s eye appearance) and visual field defects (paracentral scotomas) in patients receiving long-term or high-dosage 4-aminoquinoline therapy have been reported (see WARNINGS ). …

If you take too much

Signs and Symptoms: Chloroquine is very rapidly and completely absorbed after ingestion. Toxic doses of chloroquine can be fatal. As little as 1 g may be fatal in children. Toxic symptoms can occur within minutes. The symptoms of overdosage may include nausea, vomiting, headache, drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm and conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia and ventricular fibrillation, followed by sudden potentially fatal respiratory and cardiac arrest. …

Se esquecer uma dose

Tome assim que lembrar, a menos que esteja quase na hora da próxima dose. Nesse caso, pule a dose esquecida. Nunca tome duas doses de uma vez para compensar. Confira a bula, pois alguns medicamentos são diferentes.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-07-02.

Label for chloroquine (chloroquine phosphate), the active ingredient registered with NAFDAC.

Check your pack of Novalor Syrup

Add the expiry date on your pack for a full Trust Score.

Ou tire fotos da caixa
Restam 3 verificações grátis hoje Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Novalor Syrup

What is in Novalor Syrup?

Novalor Syrup contains Chloroquine (Chloroquine Phosphate) (50 mg/5 mL), as syrup, according to its NAFDAC registration record.

Is Novalor Syrup registered with NAFDAC?

Yes. Novalor Syrup is listed on the NAFDAC register under registration number 04-1636, and its registration is active as of 4 November 2026.

Has Novalor Syrup been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Novalor Syrup in our automatically synced alert list.

How can I check that my pack of Novalor Syrup is genuine?

Run a free authenticity scan with the NAFDAC number 04-1636, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Novalor Syrup?

Follow your prescription or the leaflet in your pack. The official label says: The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 500 mg tablet of Chloroquine phosphate contains the equivalent of 300 mg chloroquine base. In infants and children the dosage is preferably calculated by body weight. Prophylaxis against chloroquine-sensitive Plasmodium species Adult Dose: The dosage for prophylaxis is 500 mg (=…

What is Novalor Syrup used for?

Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria becaus (Summarised from the official U.S. FDA label for chloroquine (chloroquine phosphate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Novalor Syrup? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.